A systematic literature review of quality of life among people living with HIV/AIDS in China

Liya Fan, Zhiliu Tang, Ian Jacob, Yi Chen, Huanyu Li, Yu Zhang
{"title":"A systematic literature review of quality of life among people living with HIV/AIDS in China","authors":"Liya Fan, Zhiliu Tang, Ian Jacob, Yi Chen, Huanyu Li, Yu Zhang","doi":"10.54844/hd.2024.0005","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to systematically characterize the health-related quality of life (HRQoL) among people living with \nHIV/AIDS (PLWHA) in China. \nMethods: The systematic literature searching was conducted from database establishment until June 28 2023 (PubMed, \nEmbase, ISPOR, CNKI, Wanfang, and VIP Database), and health utility values were estimated using mapping algorithms. \nResults: 11,290 literatures were screened, of which 290 met the eligibility criteria without PLWHA restriction and covered 18 \ndifferent scales. Inclusion criterion: (1) Studies investigating Chinese PLWHA, (2) Studies that utilize multi-dimensional HRQoL \nscales, (3) Sample size ≥100 participants, and exclusion criterion: (1) Studies not targeting on Chinese PLWHA, (2) Studies utilizing \nunspecified or undefined scales, (3) Studies in which the scale scores for different domains were not reported, (4) Non-research \nmaterials (editorials, correspondences, theses, etc., (5) Duplicate studies. Analysis was based on 179 studies with the most \nfrequently used top 3 scales, including the 36-item short form survey (SF-36) in 64 (22%) studies, World Health Organization \nQuality of Life Questionnaire for HIV Brief Version (WHOQOL-HIV-BREF) in 58 (20%) studies, and medical outcomes study HIV \nhealth survey (MOS-HIV) in 57 (20%) studies. \nThe 179 studies were published between 2007 and 2023. 13 studies started since 2020 after COVID-19 outbreak. 122 \nwere non-interventional studies and 57 were prospective interventional controlled trials. 137 out of 159 studies where gender \ninformation was available reported a higher proportion of male participants. Only 3 studies published before 2020 specified the \ntreatment regimens, all included in the National Free Antiretroviral Treatment Program (NFATP) and none was targeting integrase \nstrand transfer inhibitor (INSTI). \nAcross these 3 scales, non-interventional studies consistently indicated lower HRQoL in PLWHA compared to the general \npopulation, while in prospective trials it indicated HRQoL improvements through interventions like nursing care, management \nstrategies and highly active antiretroviral therapy. \nMedian utility values estimated from the MOS-HIV were 0.81 and 0.78, respectively, based on two mapping algorithms. \nSubgroup analyses indicated lower utility in AIDS patients compared to HIV-infected individuals, with differences ranging from \n0.01 to 0.09 across various studies using different mapping algorithms. Both groups were associated with lower utility than \nthat in general population in China. \nConclusion: The overall HRQoL among Chinese PLWHA is worse than the that in general population, emphasizing the urgent \nneed for effective treatment strategies to improve the HRQoL for PLWHA. \nKey words: people living with HIV/AIDS, quality of Life, China, systematic literature review","PeriodicalId":430023,"journal":{"name":"Health Decision","volume":"59 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Decision","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54844/hd.2024.0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aims to systematically characterize the health-related quality of life (HRQoL) among people living with HIV/AIDS (PLWHA) in China. Methods: The systematic literature searching was conducted from database establishment until June 28 2023 (PubMed, Embase, ISPOR, CNKI, Wanfang, and VIP Database), and health utility values were estimated using mapping algorithms. Results: 11,290 literatures were screened, of which 290 met the eligibility criteria without PLWHA restriction and covered 18 different scales. Inclusion criterion: (1) Studies investigating Chinese PLWHA, (2) Studies that utilize multi-dimensional HRQoL scales, (3) Sample size ≥100 participants, and exclusion criterion: (1) Studies not targeting on Chinese PLWHA, (2) Studies utilizing unspecified or undefined scales, (3) Studies in which the scale scores for different domains were not reported, (4) Non-research materials (editorials, correspondences, theses, etc., (5) Duplicate studies. Analysis was based on 179 studies with the most frequently used top 3 scales, including the 36-item short form survey (SF-36) in 64 (22%) studies, World Health Organization Quality of Life Questionnaire for HIV Brief Version (WHOQOL-HIV-BREF) in 58 (20%) studies, and medical outcomes study HIV health survey (MOS-HIV) in 57 (20%) studies. The 179 studies were published between 2007 and 2023. 13 studies started since 2020 after COVID-19 outbreak. 122 were non-interventional studies and 57 were prospective interventional controlled trials. 137 out of 159 studies where gender information was available reported a higher proportion of male participants. Only 3 studies published before 2020 specified the treatment regimens, all included in the National Free Antiretroviral Treatment Program (NFATP) and none was targeting integrase strand transfer inhibitor (INSTI). Across these 3 scales, non-interventional studies consistently indicated lower HRQoL in PLWHA compared to the general population, while in prospective trials it indicated HRQoL improvements through interventions like nursing care, management strategies and highly active antiretroviral therapy. Median utility values estimated from the MOS-HIV were 0.81 and 0.78, respectively, based on two mapping algorithms. Subgroup analyses indicated lower utility in AIDS patients compared to HIV-infected individuals, with differences ranging from 0.01 to 0.09 across various studies using different mapping algorithms. Both groups were associated with lower utility than that in general population in China. Conclusion: The overall HRQoL among Chinese PLWHA is worse than the that in general population, emphasizing the urgent need for effective treatment strategies to improve the HRQoL for PLWHA. Key words: people living with HIV/AIDS, quality of Life, China, systematic literature review
关于中国艾滋病感染者生活质量的系统文献综述
研究目的本研究旨在系统描述中国艾滋病感染者(PLWHA)的健康相关生活质量(HRQoL)。研究方法系统检索自数据库建立至 2023 年 6 月 28 日的文献(PubMed、Embase、ISPOR、CNKI、万方和 VIP 数据库),并使用映射算法估算健康效用值。结果共筛选出 11,290 篇文献,其中 290 篇符合资格标准,无 PLWHA 限制,涵盖 18 个不同的量表。纳入标准:(1)调查中国 PLWHA 的研究;(2)使用多维 HRQoL 量表的研究;(3)样本量≥100 人;排除标准:(1)非针对中国 PLWHA 的研究;(2)使用未指定或未定义量表的研究;(3)未报告不同领域量表评分的研究;(4)非研究资料(社论、通讯、论文等);(5)重复研究。分析基于 179 项研究中最常使用的前 3 个量表,包括 64 项(22%)研究中的 36 项短表调查(SF-36)、58 项(20%)研究中的世界卫生组织 HIV 生活质量问卷简易版(WHOQOL-HIV-BREF)和 57 项(20%)研究中的医疗结果研究 HIV 健康调查(MOS-HIV)。这 179 项研究发表于 2007 年至 2023 年。13 项研究是在 COVID-19 爆发后于 2020 年开始的。122 项为非干预性研究,57 项为前瞻性干预对照试验。在有性别信息的 159 项研究中,137 项研究报告了较高比例的男性参与者。只有 3 项在 2020 年前发表的研究明确说明了治疗方案,这些方案都包含在国家免费抗逆转录病毒治疗计划(NFATP)中,而且没有一项研究针对整合酶链转移抑制剂(INSTI)。在这 3 个量表中,非干预性研究一致表明,与普通人群相比,PLWHA 的 HRQoL 较低,而前瞻性试验则表明,通过护理、管理策略和高活性抗逆转录病毒疗法等干预措施,HRQoL 有所改善。根据两种绘图算法,MOS-HIV 估算出的效用中值分别为 0.81 和 0.78。亚组分析表明,艾滋病患者的效用值低于 HIV 感染者,在使用不同映射算法的各项研究中,差异从 0.01 到 0.09 不等。与中国普通人群相比,这两个群体的效用都较低。结论中国艾滋病病毒感染者和艾滋病患者的总体HRQoL低于普通人群,因此迫切需要有效的治疗策略来改善艾滋病病毒感染者和艾滋病患者的HRQoL。关键词:艾滋病感染者、生活质量、中国、系统文献综述
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信